<DOC>
	<DOCNO>NCT02408978</DOCNO>
	<brief_summary>Oxford Pharmascience Ltd ( Sponsor ) develop new naproxen tablet formulation ( study drug , OXP005 ) , potential treatment rheumatic painful condition . The study compare study drug already market formulation prescription strength naproxen ( NaprosynÂ® reference product ) look relative impact product gastroduodenal ( GD ) irritation perform specialist procedure call endoscopy ( specifically , gastroscopy ) . The safety tolerability study drug also assess .</brief_summary>
	<brief_title>Pilot Study OXP005 Assess Gastroduodenal Irritation</brief_title>
	<detailed_description />
	<mesh_term>Naproxen</mesh_term>
	<criteria>Healthy male female subject Healthy , normal upper GI tract indicate ulcer erosion baseline , assessed gastroenterologist conduct endoscopy ( ie Lanza score 0 stomach duodenum ) H. pylorus negative Clinically significant abnormal laboratory parameter Any clinically significant disease condition affect haematopoietic , cardiovascular , renal , hepatic , endocrine , pulmonary , centralcnervous , immunological , dermatological , GI body system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>